Literature DB >> 21930609

B-cell responses during primary and secondary dengue virus infections in humans.

Anuja Mathew1, Kim West, Siripen Kalayanarooj, Robert V Gibbons, Anon Srikiatkhachorn, Sharone Green, Daniel Libraty, Smita Jaiswal, Alan L Rothman.   

Abstract

Low-avidity serotype-cross-reactive antibodies are hypothesized to play a key role in triggering severe disease in patients with secondary dengue virus (DENV) infection. However, there is little systematic information about the frequency, avidity, and cross-reactivity of DENV-specific B cells in individuals experiencing primary instead of secondary infection. We compared DENV-specific B-cell responses in a cohort of Thai children with primary or secondary DENV infection. B cells specific for DENV precursor membrane protein, envelope (E) protein, and nonstructural protein 1 were detectable in immune peripheral blood mononuclear cells with the highest frequencies of DENV E-specific B cells detected in patients experiencing primary DENV-1 infections. DENV E-specific B cells were highly serotype-specific after primary DENV infections, whereas most E-specific B cells in patients with secondary infection were serotype-cross-reactive and secreted antibodies with higher avidity to heterologous DENV serotypes. Our data suggest that the minor populations of serotype-cross-reactive B cells generated by primary DENV infection are preferentially expanded during secondary DENV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930609      PMCID: PMC3222107          DOI: 10.1093/infdis/jir607

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins.

Authors:  A K Falconar
Journal:  Arch Virol       Date:  1999       Impact factor: 2.574

2.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Neutralization and antibody-dependent enhancement of dengue viruses.

Authors:  Scott B Halstead
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

4.  Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.

Authors:  Shane Crotty; Rachael D Aubert; John Glidewell; Rafi Ahmed
Journal:  J Immunol Methods       Date:  2004-03       Impact factor: 2.303

5.  Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors:  Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

6.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

7.  An in-depth analysis of original antigenic sin in dengue virus infection.

Authors:  Claire M Midgley; Martha Bajwa-Joseph; Sirijitt Vasanawathana; Wannee Limpitikul; Bridget Wills; Aleksandra Flanagan; Emily Waiyaiya; Hai Bac Tran; Alison E Cowper; Pojchong Chotiyarnwong; Pojchong Chotiyarnwon; Jonathan M Grimes; Sutee Yoksan; Prida Malasit; Cameron P Simmons; Juthathip Mongkolsapaya; Gavin R Screaton
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

8.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

Review 9.  Antigenic structure of flavivirus proteins.

Authors:  John T Roehrig
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

10.  Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status.

Authors:  Huynh T L Duyen; Tran V Ngoc; Do T Ha; Vu T T Hang; Nguyen T T Kieu; Paul R Young; Jeremy J Farrar; Cameron P Simmons; Marcel Wolbers; Bridget A Wills
Journal:  J Infect Dis       Date:  2011-02-18       Impact factor: 5.226

View more
  41 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

Authors:  Bruno Guy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

2.  Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.

Authors:  Wen-Yang Tsai; Anna Durbin; Jih-Jin Tsai; Szu-Chia Hsieh; Stephen Whitehead; Wei-Kung Wang
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

3.  Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice.

Authors:  Smita Jaiswal; Kenneth Smith; Alejandro Ramirez; Marcia Woda; Pamela Pazoles; Leonard D Shultz; Dale L Greiner; Michael A Brehm; Anuja Mathew
Journal:  Exp Biol Med (Maywood)       Date:  2014-08-14

Review 4.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 5.  The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Curr Opin Virol       Date:  2018-03-26       Impact factor: 7.090

6.  Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.

Authors:  Awadalkareem Adam; Marcia Woda; Sonia Kounlavouth; Alan L Rothman; Richard G Jarman; Josephine H Cox; Julie E Ledgerwood; Gregory D Gromowski; Jeffrey R Currier; Heather Friberg; Anuja Mathew
Journal:  J Immunol       Date:  2018-11-09       Impact factor: 5.422

7.  Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells.

Authors:  Heather Friberg; Smita Jaiswal; Kim West; Marvin O'Ketch; Alan L Rothman; Anuja Mathew
Journal:  Viral Immunol       Date:  2012-08-30       Impact factor: 2.257

8.  Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions.

Authors:  Marcia Woda; Heather Friberg; Jeffrey R Currier; Anon Srikiatkhachorn; Louis R Macareo; Sharone Green; Richard G Jarman; Alan L Rothman; Anuja Mathew
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

9.  Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients.

Authors:  Tatiana M Garcia-Bates; Marli T Cordeiro; Eduardo J M Nascimento; Amanda P Smith; Klécia M Soares de Melo; Sean P McBurney; Jared D Evans; Ernesto T A Marques; Simon M Barratt-Boyes
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

10.  Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue.

Authors:  Paulina Andrade; Parnal Narvekar; Magelda Montoya; Daniela Michlmayr; Angel Balmaseda; Josefina Coloma; Eva Harris
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.